This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Ankylosing Spondylitis, Multiple Sites in Spine강직척추염, 척추의 여러 부위

ICD-10M45.0
Synonyms / related termsAnkylosing spondylitis with multisite involvement, multisite form of Bechterew disease, bamboo spine
Special Copayment ReductionV140 — Severe intractable disease (copayment 10%, 5 years)
Main age of onsetOnset most common at ages 15-35; multisite involvement mainly appears in patients with long-standing disease

Contents

s1History
s2Causes
s3Genetics
s4General epidemiology
s5Pathophysiology
s6Symptoms
s7Signs
s8Screening
s9Diagnosis
s10Treatment
s11Prognosis
s12Prevention
s13References

1. History

Ankylosing spondylitis (AS) is an ancient disease, with evidence of spinal bony fusion reported in ancient Egyptian mummies (about 5000 BC). In modern medicine, Bernard Connor first described a specimen of completely bony-fused spine in 1693, and in 1897 Bechterew, Marie, and Strümpell independently published clinical reports, giving rise to the name 'Bechterew disease.' With the introduction of radiography in the early 20th century, the characteristic radiographic findings of sacroiliitis and spinal bony fusion were described. In 1973, the strong association between HLA-B27 and AS was discovered, laying the foundation for genetic-immunological understanding, and in 1984 the modified New York criteria were adopted as the standard for AS diagnosis. In the 2000s, MRI made it possible to detect acute inflammatory findings in the sacroiliac joints and spine, and the concept of early diagnosis at a stage before radiographic changes developed. With the introduction of TNF inhibitors (etanercept, infliximab, adalimumab) for AS treatment after 2003, the treatment paradigm shifted, and after 2015 IL-17A inhibitors (secukinumab, ixekizumab) were added, widening treatment options. M45.0 (multiple sites in the spine) is the most extensive anatomical subtype of AS, in which lesions exist across two or more spinal regions such as the cervical, thoracic, and lumbar spine, and represents the clinical picture of typical advanced AS.

2. Causes

The cause of AS is understood as an interaction between genetic predisposition and environmental triggers. HLA-B27 is the most important genetic risk factor, and the risk of developing AS in HLA-B27-positive individuals is about 100 times higher than in the general population. However, only about 5-10% of the HLA-B27-positive population develop AS, so the roles of non-HLA genetic factors and environmental factors are important. Gut microbiome abnormalities are increasingly emerging as important, and there is a hypothesis that specific gut bacteria such as Klebsiella pneumoniae and Clostridium spp. may induce autoimmunity of the spinal joints through molecular mimicry with HLA-B27. Supporting evidence is also accumulating for the 'enthesis stress' hypothesis, in which repetitive mechanical loading (at enthesis sites) and microdamage trigger an immune response. Smoking is a risk factor that accelerates radiographic progression of AS and reduces response to TNF inhibitor treatment. In M45.0, which involves multiple spinal sites simultaneously, extensive immune activation and a long disease course are often in the background.

3. Genetics

The heritability of AS is estimated at about 90% in twin studies, suggesting a strong genetic basis. HLA-B27 explains about 20-30% of the genetic predisposition to AS, and among the 60 or so subtypes of HLA-B27, B*27:02, B*27:04, and B*27:05 are most strongly associated with AS. In Koreans, B*27:04 and B*27:05 are the main associated subtypes. Besides HLA-B27, polymorphisms of ERAP1 (endoplasmic reticulum aminopeptidase 1) and ERAP2 modify the MHC class I antigen presentation pathway and modulate AS risk. Polymorphisms of IL23R, IL12B, and STAT3 are involved in regulating the IL-23/IL-17 axis and increase AS susceptibility. More than 100 additional AS-associated gene loci have been identified through GWAS (genome-wide association studies). Patients with multisite spinal involvement (M45.0) tend to have a higher HLA-B27 positivity rate and a higher polygenic risk score than those with single-site involvement.

4. General epidemiology

The worldwide prevalence of AS is estimated at about 0.1-0.5% of the population, and in Korea about 0.3-0.5% is reported. AS prevalence also differs according to ethnic differences in HLA-B27 prevalence (about 8-10% in Northern Europe, about 4-5% in Korea). Onset is mostly at ages 15-35, and onset after age 45 is rare. Men are affected about 2-3 times more than women, and men tend to show more severe spinal ankylosis. M45.0 (multisite spinal involvement) is common in patients with a long AS disease duration, and radiographic progression is faster in those who did not receive early diagnosis and treatment. Bony fusion of the entire spine (bamboo spine) progresses over decades, and in patients with multisite involvement a high proportion eventually reach complete ankylosis. Cardiovascular disease (aortic root dilation, conduction disturbance, ischemic heart disease) is also more common in patients with multisite involvement.

5. Pathophysiology

The core pathology of AS begins with chronic inflammation of the entheses (the sites where ligaments, tendons, and joint capsules attach to bone). Abnormal misfolding of heavy chain protein in HLA-B27-positive cells triggers the endoplasmic reticulum stress response and promotes IL-23 secretion. IL-23 activates IL-17A-producing ILC3 (innate lymphoid cell type 3) and CD4+ Th17 cells, and IL-17A causes bone erosion through increased RANKL expression and osteoclast activation in the synovium and entheses. At the same time, activation of the BMP (bone morphogenetic protein) and Wnt signaling pathways promotes reactive new bone formation (syndesmophytes) and bony fusion. TNF-α is the main mediator of acute inflammation, secreted by macrophages and T cells in the entheses and synovium and causing local tissue damage. HLA-B27-restricted cytotoxic responses of CD8+ T cells and NK cell activation also contribute to the pathology. In multisite involvement (M45.0), overactivation of the systemic IL-23/IL-17 axis and simultaneous multifocal inflammation at extensive enthesis sites underlie radiographic progression.

6. Symptoms

The characteristic symptom of M45.0 multisite spinal involvement is chronic inflammatory low back pain spanning multiple spinal segments, worsening at rest and improving with exercise. Morning stiffness lasts 45 minutes or more, and patients tend to wake at night because of pain, cough, and then change position. With involvement of the entire spine, decreased cervical range of motion (bending forward, turning sideways), increased thoracic kyphosis (hyperkyphosis), and loss of lumbar lordosis appear in combination, with prominent postural deformity. Reduced chest expansion due to thoracic involvement can cause dyspnea on exertion. With extensive spinal involvement, spinal instability increases, so fractures can occur even with minor trauma, and there is a high risk of spinal cord or nerve root injury at the fracture site. Uveitis (anterior uveitis) occurs in about 30-40% of AS patients and is also frequent in patients with multisite involvement. Fatigue, weight loss, and general malaise accompany the condition, reflecting the extensive inflammatory state.

7. Signs

On physical examination, the Schober test (increase of less than 5 cm on lumbar flexion) and the modified Schober test (increase of less than 10 cm) quantify restriction of lumbar range of motion. Chest expansion measurement (at the level of the 4th intercostal space; less than 2.5 cm is abnormal) reflects the degree of thoracic-chest wall involvement. The occiput-to-wall distance (normal 0 cm) and the tragus-to-wall distance measure cervical flexion deformity. On whole-body postural observation, hyperthoracic kyphosis, loss of lumbar lordosis, hip flexion contracture, and forward stooping posture are typical. Because of enthesophytes and spinal ligament ossification, tenderness on percussion of the spine is found at multiple sites. Provocation tests of the sacroiliac joint (Patrick test, direct sacroiliac joint compression) are positive. In patients with multisite involvement, the BASMI (Bath AS Metrology Index) score is high, and functional assessment (BASFI: Bath AS Functional Index) is also poor. The risk of vertebral compression fracture due to secondary osteoporosis increases, and wedge deformity of the vertebral bodies may be observed on radiographs.

8. Screening

HLA-B27 testing is useful in supporting the diagnosis of AS but is not used as the sole basis for diagnosis (limited positive predictive value). ESR and CRP reflect inflammatory activity but may be within the normal range in about 50% of AS patients. On whole-spine radiographs (anteroposterior and lateral, including the pelvis), the sacroiliitis grade, vertebral corner lesions (shiny corner, Romanus lesion), syndesmophytes, and the presence of bamboo spine are evaluated. Disease activity and functional status are measured regularly with the BASMI, BASFI, and ASDAS (Ankylosing Spondylitis Disease Activity Score) or BASDAI (Bath AS Disease Activity Index). Bone density (DEXA) is essential for evaluating secondary osteoporosis, and patients with whole-spine involvement have a particularly high fracture risk. Electrocardiography and echocardiography are performed to evaluate aortic valve regurgitation and conduction disturbance. Pulmonary function tests (FVC, FEV1, TLC) evaluate chest wall restrictive respiratory impairment.

9. Diagnosis

AS diagnosis is based on the 1984 modified New York criteria: (1) inflammatory low back pain lasting 3 months or more, (2) restricted lumbar range of motion (anteroposterior and lateral), (3) reduced chest expansion (relative to age- and sex-specific normal values), (4) radiographic criterion: bilateral sacroiliitis grade 2 or higher, or unilateral sacroiliitis grade 3-4. The diagnosis is definite when at least 1 clinical criterion + the radiographic criterion are met. MRI (short tau inversion recovery, STIR) detects active inflammation (bone marrow edema) in the sacroiliac joints and spine before radiographic changes and enables early diagnosis at the non-radiographic spondyloarthritis (nr-axSpA) stage. M45.0 is a code specifying that lesions span multiple spinal regions, and multisite involvement must be confirmed on radiographs or MRI. The ASAS 2009 axSpA classification criteria include MRI or HLA-B27 positivity, enabling early diagnosis. In multisite involvement, neurological evaluation (excluding myelopathy and cauda equina syndrome) is needed.

10. Treatment

The goals of AS treatment are symptom control, maintenance of function, suppression of radiographic progression, and prevention of extra-articular complications. NSAIDs (indomethacin, naproxen, celecoxib) are the first-line drugs, and there is evidence that continuous administration suppresses radiographic progression. Physical therapy and exercise therapy (swimming, extension exercises) are essential for posture correction and maintenance of function and are combined with drug treatment. When the response to NSAIDs is inadequate, TNF inhibitors (adalimumab, etanercept, infliximab, certolizumab, golimumab) are administered. IL-17A inhibitors (secukinumab, ixekizumab) are an alternative in case of TNF inhibitor failure or coexisting inflammatory bowel disease. JAK inhibitors (tofacitinib, upadacitinib) are recommended in the ASAS/EULAR 2022 guidelines as an option after failure of TNF/IL-17 inhibitors. Surgery (spinal corrective osteotomy) in patients with whole-spine involvement is considered when severe flexion deformity causes loss of forward vision and dysphagia. Osteoporosis treatment (bisphosphonate, anti-RANKL) is added to reduce fracture risk.

11. Prognosis

AS is a chronic progressive disease, but the clinical course differs greatly between individuals. Radiographic progression occurs fastest within 10 years of onset, and the prognosis is poor when radiographic changes have already progressed at diagnosis. Patients with multisite spinal involvement (M45.0) show extensive syndesmophyte formation, rapid functional decline, and a high need for surgery. Elevated baseline CRP, male sex, smoking, HLA-B27 positivity, the degree of initial radiographic damage, and hip involvement are predictors of poor radiographic progression. TNF inhibitor treatment markedly improves function and quality of life, but its effect on suppressing radiographic progression is incomplete. Cardiovascular complications (aortic regurgitation, conduction disturbance, IHD) are major contributors to long-term mortality. When neurological injury occurs after a spinal fracture, the prognosis is extremely poor. Active exercise rehabilitation and early administration of TNF/IL-17 inhibitors improve long-term functional outcomes.

12. Prevention

There is currently no established method for preventing the onset of AS itself. However, early diagnosis and treatment initiation can slow radiographic progression and functional decline. Smoking cessation helps suppress radiographic progression and improve response to TNF inhibitor treatment. Regular aerobic exercise (swimming, cycling) and spinal extension exercise programs delay postural deformity and functional decline. Osteoporosis prevention (calcium and vitamin D supplementation, weight-bearing exercise) is essential for reducing fracture risk. In patients with whole-spine involvement, management of fall risk (environmental adjustment, balance training) is important. Regular eye examinations prevent visual impairment through early detection and treatment of uveitis. Control of cardiovascular risk factors (blood pressure, lipids, blood glucose) is important for lowering the increased cardiovascular mortality risk in AS.

13. References

1. van der Linden S, et al. Evaluation of diagnostic criteria for ankylosing spondylitis. Arthritis Rheum. 1984;27(4):361-8.

2. Sieper J, et al. Ankylosing spondylitis: an overview. Ann Rheum Dis. 2002;61(Suppl 3):iii8-18.

3. Braun J, et al. ASAS/EULAR recommendations for the management of ankylosing spondylitis. Ann Rheum Dis. 2011;70(6):896-904.

4. Poddubnyy D, et al. Rates and predictors of radiographic spinal progression in AS. Ann Rheum Dis. 2011;70(8):1369-74.

5. Baraliakos X, et al. MRI in AS: patterns of spinal changes. Rheumatology. 2017;56(3):421-32.

6. Reveille JD. Genetics of spondyloarthritis — beyond the MHC. Nat Rev Rheumatol. 2012;8(5):296-304.

7. Klingberg E, et al. Osteoporosis in ankylosing spondylitis — prevalence, risk factors and methods of assessment. Arthritis Res Ther. 2012;14(3):R108.

8. Ramiro S, et al. ASAS-EULAR recommendations for AS management: 2022 update. Ann Rheum Dis. 2023;82(1):19-34.

9. Kim TH, et al. Spondyloarthropathies in Korea: prevalence and clinical characteristics. J Korean Med Sci. 2021;36(12):e96.

10. Wanders AJ, et al. NSAIDs inhibit radiographic progression in AS. Arthritis Rheum. 2005;52(6):1756-65.